Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Ben Markman"'
Autor:
Quincy Chu, MD, Natasha B. Leighl, MD, Veerle Surmont, MD, Carla van Herpen, MD, PhD, Anne Sibille, MD, Ben Markman, MD, Stephen Clarke, MD, Rosalyn A. Juergens, MD, PhD, Mirelis Acosta Rivera, MD, Vladimir Andelkovic, MD, Charles M. Rudin, MD, PhD, Stephanie Snow, MD, Dong-Wan Kim, MD, Michael Sanatani, MD, Hongxia Lin, PhD, Kinjal Sanghavi, PhD, Sarah Tannenbaum-Dvir, MD, Paul Basciano, MD, Deanne Lathers, PhD, Katarzyna Urbanska, PhD, Georgia Kollia, PhD, Chunsheng He, PhD, Andrew DiPiero, BS, Yu Liu, MD, PhD, Neal Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100400- (2022)
Introduction: Fucosyl-GM1 is a monosialoganglioside with limited expression in healthy tissues and high expression on SCLC cells. BMS-986012 is a nonfucosylated, first-in-class, fully human immunoglobulin G1 monoclonal antibody that binds to fucosyl-
Externí odkaz:
https://doaj.org/article/f5bd2944b1a6435ab4a355125a671725
Autor:
Siddharth Menon, Amy Davies, Sophia Frentzas, Cheryl‐Ann Hawkins, Eva Segelov, Daphne Day, Ben Markman
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background With the rapid influx of novel anti‐cancer agents, phase I clinical trials in oncology are evolving. Historically, response rates on early phase trials have been modest with the clinical benefit and ethics of enrolment debated.
Externí odkaz:
https://doaj.org/article/78eae5c9830d41b9a993510cdf6bab8c
Autor:
Linda Mileshkin, Ben Markman, Oliver Klein, Damien Kee, Jonathan Cebon, Andreas Behren, Matteo Carlino, Bo Gao, Jessica da Gama Duarte, Luke Quigley, Louise Jackett, Richelle Linklater, Andrew Strickland, Clare Scott, Jodie Palmer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/6766e0f0fbac49fbb8002327f10273b3
Autor:
Belinda Lee, Lucy Gately, Sheau Wen Lok, Ben Tran, Margaret Lee, Rachel Wong, Ben Markman, Kate Dunn, Vanessa Wong, Matthew Loft, Azim Jalili, Angelyn Anton, Richard To, Miles Andrews, Peter Gibbs
Publikováno v:
Cancers, Vol 14, Iss 17, p 4131 (2022)
Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we describe the
Externí odkaz:
https://doaj.org/article/4a5f3038a4dd4774bea440d529c2d413
Autor:
Oliver Klein, Clare Senko, Matteo S Carlino, Ben Markman, Louise Jackett, Bo Gao, Caroline Lum, Damien Kee, Andreas Behren, Jodie Palmer, Jonathan Cebon
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Background: Adrenocortical carcinoma is a rare malignancy, with poor prognosis and limited treatment options for patients with advanced disease. Chemotherapy is the current standard first-line treatment, providing only a modest survival benefit. Ther
Externí odkaz:
https://doaj.org/article/7f2fc651c58842519396e8f5afbfd47f
Autor:
Bhumsuk Keam, Jayesh Desai, Ben Markman, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigationa
Externí odkaz:
https://doaj.org/article/1f2f609e135d4807be9e954535daa4f0
Autor:
Enriqueta Felip, Josep Tabernero, Maria De Santis, Emile Voest, Mark Robson, Fatima Cardoso, Elisabeth G E de Vries, Fedro Alessandro Peccatori, Svetlana Jezdic, Giannis Mountzios, Smita Bhatia, Alexandru Eniu, Luzia Travado, Ulrich Keilholz, Jonas Bergh, Jan Buckner, Friedrich Stiefel, Ahmad Awada, Cristiana Sessa, Olivier Michielin, Marc Ernstoff, Ben Markman, Lisa Licitra, Rossana Berardi, Jill Gilbert, Lidia Schapira, Eva Schernhammer, Jeffrey S Weber, Heinz-Josef Lenz, Piotr Rutkowski, Jennifer Duff, Axel Grothey, Yuichiro Ohe, Saskia Litiere, Hans Wildiers, Christian Dittrich, Michael Kosty, Doug Pyle, Nagi El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne, Susana Banerjee, Jan Bogaerts, Paolo Casali, Edward Chu, Julia Lee Close, Bertrand Coiffier, Roisin Connolly, Sarah Coupland, Luigi De Petris, Don S Dizon, Linda R Duska, Martin F Fey, Nicolas Girard, Andor W J M Glaudemans, Priya K Gopalan, Stephen M Hahn, Diana Hanna, Christian Herold, Jørn Herrstedt, Krisztian Homicsko, Dennie V Jones, Lorenz Jost, Saad Khan, Alexander Kiss, Claus-Henning Köhne, Rainer Kunstfeld, Stuart Lichtman, Thomas Lion, Lifang Liu, Patrick J Loehrer, Merry Jennifer Markham, Marius Mayerhoefer, Johannes G Meran, Elizabeth Charlotte Moser, Timothy Moynihan, Torsten Nielsen, Kjell Öberg, Antonio Palumbo, Michael Pfeilstöcker, Chandrajit Raut, Scot C Remick, Roberto Salgado, Martin Schlumberger, Hans-Joachim Schmoll, Lowell Schnipper, Charles L Shapiro, Julie Steele, Cora N Sternberg, Florian Strasser, Roger Stupp, Richard Sullivan, Marcel Verheij, Everett Vokes, Jamie Von Roenn, Yosef Yarden
Publikováno v:
ESMO Open, Vol 1, Iss 5 (2016)
The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. Firs
Externí odkaz:
https://doaj.org/article/03442ec458e245ef83ebe8453a3f265c
Autor:
Jayesh Desai, Peter Fong, Victor Moreno, Sophia Frentzas, Tarek Meniawy, Ben Markman, Mark Voskoboynik, Tahmina Rahman, Nageshwar Budha, John Wu, Jin Marlow, Silu Yang, Emiliano Calvo, Juan Martin-Liberal
Publikováno v:
British Journal of Cancer. 128:1418-1428
Background Many patients do not respond or eventually relapse on treatment with programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors due to secondary or acquired resistance; therefore, there is a need to inve
Autor:
Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Publikováno v:
Clinical Cancer Research. 29:1017-1030
Purpose:BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches being developed clinically with oral BRAF inhibitors combined with EGFR-targeting antibodies. While compelling preclinical d
Autor:
Richard A. Miller, Stephen B. Willingham, Long Kwei, Ian McCaffery, Jessica Hsieh, Po Y. Ho, Brian Munneke, Rachel A. Goodwin, Daniel J. Renouf, Lyudmyla Berim, Jonathan W. Goldman, Philip Bonomi, Leonel Hernandez-Aya, Joshua D. Brody, Ginna Laport, Jason J. Luke, Daruka Mahadevan, Leisha A. Emens, Ben Markman, Matthew J. Riese, Amy M. Weise, Shivaani Kummar, Brian I. Rini, Dale R. Shepard, Matthew D. Hellmann, Brett G.M. Hughes, Saby George, Toni K. Choueiri, Rebecca S. Heist, Mario Sznol, John D. Powderly, Andrew Hotson, Lawrence Fong
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1a4eb0824258054770e529fd0c7d5f1
https://doi.org/10.1158/2159-8290.c.6547840.v1
https://doi.org/10.1158/2159-8290.c.6547840.v1